10-K: Aquestive Therapeutics Faces Anaphylm Delay, Libervant Setback

Aquestive Therapeutics reports a significant net loss increase and a delay in Anaphylm's FDA approval, alongside a legal setback for Libervant, despite successful capital raises.

Summary

• Net loss for the year ended December 31, 2025, increased to $83,784 thousand, up from $44,137 thousand in 2024.
• Total revenues decreased by 23% to $44,545 thousand in 2025, down from $57,561 thousand in 2024.
• Anaphylm (dibutepinephrine) Sublingual Film received a Complete Response Letter (CRL) from the FDA on January 30, 2026, citing deficiencies in the Human Factors (HF) validation study related to pouch opening and film placement.
• Resubmission of the Anaphylm NDA is estimated for Q3 2026, assuming completion of new HF and PK studies.
• Libervant (diazepam) Buccal Film's FDA approval for ARS patients aged two to five years was vacated by a U.S. District Court ruling on February 14, 2025, converting it to 'tentative approval' and halting marketing activities.
• The FDA is appealing the Libervant ruling, and new legislation amending the Orphan Drug Act may impact the appeal's outcome.
• Cash and cash equivalents increased to $121,169 thousand as of December 31, 2025, from $71,546 thousand in 2024, primarily due to financing activities.
• The company completed a $85,000 thousand underwritten public offering in August 2025 and utilized its ATM facility for $21,229 thousand in net proceeds in 2025.
• A purchase and sale agreement with RTW Investments LP for $75,000 thousand, contingent on Anaphylm FDA approval and 13.5% Notes refinancing, had its Marketing Approval Deadline extended to June 30, 2027.
• Suboxone, a key licensed product, saw a $3,482 thousand decrease in revenues in 2025 and its branded products retain approximately 24% film market share amidst generic competition.
• The company faces product liability lawsuits related to dental injuries from Suboxone use in both the U.S. and Canada.
• Principal payments on the 13.5% Senior Secured Notes, totaling $45,000 thousand, are set to commence in June 2026.
• R&D expenses decreased by 15% to $17,192 thousand in 2025, mainly due to lower Anaphylm clinical trial costs.
• Selling, general and administrative expenses increased by 59% to $79,849 thousand in 2025, driven by higher legal-related expenses ($14,300 thousand) and commercial spending for Anaphylm launch preparation ($9,600 thousand).
• Indivior accounted for approximately 73% of total revenues in 2025, highlighting significant customer concentration risk.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing negatively due to significant setbacks for key pipeline assets Anaphylm and Libervant, coupled with increased net losses and declining revenues from existing products, despite successful capital raises.

Positives

• Cash and cash equivalents significantly increased to $121,169 thousand as of December 31, 2025, providing near-term liquidity.
• Successful capital raises through a $85,000 thousand underwritten public offering and $21,229 thousand from the ATM facility in 2025 strengthened the financial position.
• Anaphylm's clinical trial results regarding PK biocomparability to approved auto-injectors (EpiPen and Auvi-Q) were not questioned in the FDA's CRL, indicating strong efficacy data.
• No Chemistry, Manufacturing, and Controls (CMC) issues were noted in the Anaphylm CRL, suggesting manufacturing readiness.
• The EMA provided positive feedback that no further clinical trials are needed for Anaphylm prior to regulatory submission in Europe, and submissions are planned for Europe and Canada in 2026.
• The Marketing Approval Deadline for the RTW Purchase and Sale Agreement for Anaphylm was extended to June 30, 2027, providing more time to address FDA concerns.
• The company received a $1,402 thousand Employee Retention Tax Credit (ERTC) refund in April 2025, contributing to other income.

Negatives

• Net loss significantly increased to $83,784 thousand in 2025 from $44,137 thousand in 2024.
• Total revenues decreased by 23% to $44,545 thousand in 2025, primarily due to decreases in license and royalty revenue and proprietary product revenue.
• Anaphylm's FDA approval was delayed by a Complete Response Letter (CRL) on January 30, 2026, due to deficiencies in the Human Factors validation study.
• Libervant's U.S. market access for ARS patients aged two to five years was halted, with its approval converted to 'tentative approval' following a court ruling.
• Suboxone revenues decreased by $3,482 thousand in 2025, and its market share continues to erode due to generic competition.
• Selling, general and administrative expenses increased substantially by 59% ($29,669 thousand) in 2025, driven by higher legal expenses and Anaphylm launch preparations.
• The company faces significant customer concentration, with Indivior accounting for approximately 73% of total revenues in 2025.
• Principal payments on the $45,000 thousand 13.5% Senior Secured Notes commence in June 2026, which will significantly reduce available cash unless refinanced or amended.

Risks

• Inability to successfully address the FDA's concerns and identified deficiencies in the Anaphylm NDA, particularly regarding the Human Factors validation study, could prevent or further delay approval.
• Failure to generate sufficient clinical and human factor data for Anaphylm, including PK/PD comparability data, could impede FDA approval.
• The need for substantial additional capital to fund operations, commercialize Anaphylm (if approved), and commence principal payments on the 13.5% Notes starting June 2026, with no assurance of availability on acceptable terms.
• Continued significant operating losses and uncertainty about achieving or sustaining profitability.
• Delays or changes to the timing, cost, and success of clinical trials for Anaphylm, AQST-108, and other product candidates.
• Intense competition from other pharmaceutical and biotechnology companies, including those with greater resources or more effective products.
• Inability to develop a sales and marketing infrastructure for commercialization of product candidates, if approved.
• Uncertainty regarding coverage and adequate reimbursement from government and private payors for products, which could hinder commercial success.
• Reliance on third-party CROs for clinical trials, with risks of delays, non-compliance, or data quality issues.
• Dependence on limited sources of supply for thin film foil and API, with potential disruptions impacting production and sales.
• Potential product liability claims or false marketing claims, particularly related to Suboxone and its active ingredient, buprenorphine.
• Cybersecurity threats, including those facilitated by AI, could lead to business interruptions, data loss, or reputational harm.
• Operational, legal, regulatory, and reputational risks associated with the deployment of AI technologies, including potential for inaccurate outputs or compliance failures.
• Adverse developments affecting the financial services industry could impair access to cash and liquidity.
• The outcome of the Neurelis FDA lawsuit challenging Libervant's approval remains uncertain, potentially impacting market access for various age groups.
• Product liability litigation related to Suboxone dental injuries in the U.S. and Canada could result in substantial costs and reputational harm.
• Changes in U.S. government policies, including tariffs and reductions in federal research funding, could adversely affect business operations and costs.
• The potential for dilution of existing stockholders' ownership if additional equity is issued to raise capital.
• The 13.5% Senior Secured Notes impose significant debt service obligations and restrictive covenants, and failure to comply could lead to default and acceleration of amounts due.

Future Outlook

The company plans to resubmit the Anaphylm NDA in Q3 2026, assuming completion of required Human Factors and PK studies, and will request accelerated review. Concurrently, regulatory submissions for Anaphylm are planned for Europe and Canada in 2026. The company expects to continue managing business costs in light of declining Suboxone revenues and will focus on developing AQST-108 and seeking licensing opportunities for proprietary products. Significant additional capital will be required to fund Anaphylm's commercialization and meet debt obligations, with principal payments on 13.5% Notes commencing in June 2026.

Management Comments

• We believe that our AdrenaVerse platform has demonstrated the ability to harness the therapeutic potential of epinephrine through highly differentiated prodrug formulations.
• We believe there is a significant market opportunity for a non-injectable, device-free, easier to administer product with a fast onset of action (Anaphylm).
• We believe Anaphylm is well positioned as a non-device based treatment option for this indication, if approved by the FDA, due to its comparable efficacy to existing auto-injector and nasal spray products, easy portability and convenience of use.
• We expect to continue to incur net losses for at least the next few years as we pursue the development efforts and commercialization of our product candidates.
• We expect to continue to manage business costs to appropriately reflect the anticipated general decline in Suboxone revenue, and other external resources or factors affecting our business.

Industry Context

StockSavvy.ai notes that the pharmaceutical industry is highly competitive, with rapid technological advancements and intense intellectual property defense. The delay in Anaphylm's FDA approval and the legal setback for Libervant highlight the significant regulatory hurdles and competitive pressures in developing and commercializing new drug candidates. The increasing market penetration of generic film-based products, as seen with Suboxone, underscores the challenge for branded products to maintain market share. The emergence of non-injection-based epinephrine delivery devices like 'neffy' also intensifies competition for Anaphylm, emphasizing the need for Aquestive's product to demonstrate clear advantages in ease of use and patient compliance. The company's reliance on third-party collaborations and manufacturing, while common, also exposes it to external risks.

Comparison to Industry Standards

• Anaphylm's clinical results demonstrating PK biocomparability to leading epinephrine auto-injectors (EpiPen and Auvi-Q) suggest it meets a high standard for efficacy in its class, potentially offering a non-invasive alternative to established products.
• The market for anaphylaxis treatment, with products like Teva's EpiPen, Viatris's EpiPen generics, Amneal Pharmaceuticals' Adrenaclick, Kaleo Inc.'s Auvi-Q, and ARS Pharmaceuticals' neffy, indicates a crowded and competitive landscape. Anaphylm's non-device, oral delivery aims to differentiate it from these existing injection and nasal spray options.
• Libervant's tentative approval and legal challenge regarding orphan drug exclusivity against Neurelis's Valtoco highlight the complexities and legal battles common in the orphan drug space, where market exclusivity can significantly impact commercial viability. This situation is a benchmark for the challenges in overcoming existing ODE.
• The decline in Suboxone's market share to approximately 24% due to generic competition is a common industry trend for branded drugs nearing patent expiration, reflecting the typical lifecycle and competitive pressures faced by pharmaceutical companies.
• The company's accumulated deficit of $446,998 thousand and continued net losses are not uncommon for a pharmaceutical company in the development stage, but the magnitude and the need for substantial additional capital for commercialization and debt repayment indicate a higher-than-average financial risk compared to more established, profitable industry players.

Management Changes

Corporate Governance

Legal Proceedings

• Neurelis, Inc. v. Aquestive Therapeutics, Inc.: A civil tort lawsuit filed in California was settled out-of-court in December 2025, with terms confidential and no concession of liability.
• Neurelis, Inc. v. Califf, et al.: A lawsuit in the U.S. District Court for the District of Columbia challenged the FDA's approval of Libervant for ARS patients aged two to five years. On February 14, 2025, the court ruled in favor of Neurelis, vacating Libervant's approval and converting it to 'tentative approval'. The FDA is appealing this ruling, and new legislation amending the Orphan Drug Act may impact the appeal.
• Suboxone Product Liability Litigation: The company is a defendant in multiple product liability lawsuits in the U.S. (consolidated as an MDL in Ohio) and three proposed class action lawsuits in Canada, alleging dental injuries from Suboxone use. Indivior has agreed to defend the company in these matters. The company's motion to dismiss the MDL was granted for all claims except design defect and punitive damages.

Stakeholder Impact

• Shareholders: Experience dilution from recent equity offerings and face uncertainty regarding future profitability, Anaphylm approval, and Libervant market access. The stock price may be volatile due to these factors.
• Patients: Potential for a non-device based epinephrine treatment (Anaphylm) for severe allergic reactions is delayed. Access to Libervant for young epilepsy patients is currently restricted due to legal proceedings.
• Employees: Potential for staff reductions or delays in R&D programs if additional funding is not secured. Management changes and compensation plans are in place.
• Creditors (13.5% Note Holders): Principal payments on the 13.5% Notes commence in June 2026, and royalty obligations are tied to Anaphylm and Libervant sales, which face delays and uncertainties.
• Customers/Licensees: Indivior (Suboxone) remains a significant revenue source but faces declining market share. Licensees for other products like Emylif and Ondif continue commercialization, but some agreements (MTPA, Haisco) were terminated.

Next Steps

• Conduct a new Human Factors validation study and a single PK study for Anaphylm to address FDA concerns.
• Resubmit the Anaphylm NDA to the FDA, estimated for Q3 2026, with a request for accelerated review.
• Pursue regulatory strategies for Anaphylm outside the United States, including submission of marketing authorization application in Europe and NDS in Canada in 2026.
• Await feedback from the MHRA in the United Kingdom regarding Anaphylm.
• Continue pre-clinical development and toxicology studies for AQST-108.
• Expect data readout from the second Phase 1 clinical trial for AQST-108 in Q2 2026.
• Await FDA response to the request for Libervant approval based on clinical superiority for ARS patients aged two to five years.
• Continue to appeal the U.S. District Court's ruling regarding Libervant's tentative approval.
• File for FDA approval for use of Libervant for ARS patients aged between 6 and 11 years prior to the expiration of Valtoco's ODE (January 2027).
• Commence principal payments on the 13.5% Senior Secured Notes in June 2026, unless refinanced or amended.
• Manage business costs to reflect anticipated decline in Suboxone revenue.
• Continue to invest in ongoing product development activities for Anaphylm and AQST-108.
• Explore additional licensing opportunities for proprietary product candidate programs or other strategic liquidity options.

Key Dates

Recommendation

The company faces significant headwinds with the FDA's CRL for Anaphylm and the legal setback for Libervant, which are critical to its future growth. While recent capital raises provide liquidity, the path to profitability remains uncertain due to ongoing losses, declining Suboxone revenue, and substantial debt obligations commencing in mid-2026. The potential for Anaphylm's approval and international expansion offers long-term upside, but the immediate regulatory and legal challenges create considerable risk. A 'hold' recommendation is appropriate, advising investors to monitor the progress on Anaphylm's resubmission, the outcome of the Libervant appeal, and the company's ability to manage its debt and achieve commercialization milestones before making further investment decisions.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, Libervant, Epinephrine, Diazepam, Sublingual Film, PharmFilm, AdrenaVerse, SEC Filing, 10-K, FDA Approval, Clinical Trials, Pharmaceuticals, Biotechnology, Orphan Drug, Anaphylaxis, Epilepsy, Drug Delivery, Capital Raise, Debt, Financial Results, Risk Factors, Corporate Governance, Cybersecurity